Fortunato Ciardiello
福尔图纳托·恰尔迪耶洛
MD, PhD
Director, Division of Medical Oncology; Full Professor of Medical Oncology, University of Campania Luigi Vanvitelli肿瘤内科科主任；路易吉·万维泰利坎帕尼亚大学肿瘤内科学正教授
👥Biography 个人简介
Fortunato Ciardiello, MD, PhD is Director of the Division of Medical Oncology and Full Professor of Medical Oncology at the University of Campania Luigi Vanvitelli in Naples, Italy. He is internationally recognized as a pioneer in EGFR-targeted therapy research in colorectal cancer and, more recently, as the leading investigator defining the scientific basis and clinical application of anti-EGFR rechallenge strategies. His group first demonstrated preclinically and then clinically that acquired RAS and EGFR extracellular domain mutations mediating resistance to anti-EGFR therapy are clonal and subject to competitive decay when anti-EGFR pressure is removed — and that ctDNA monitoring can identify the window when re-sensitive clones dominate, enabling rationally timed rechallenge. The CRICKET trial (cetuximab rechallenge) and subsequent CHRONOS trial (ctDNA-guided panitumumab rechallenge) spearheaded by his group demonstrated meaningful response rates in rechallenge settings, establishing a novel precision strategy. Prof. Ciardiello has contributed more than 400 publications and has an h-index above 95. He has been president of the Italian Association of Medical Oncology (AIOM) and serves on the ESMO Education Committee.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Anti-EGFR Rechallenge — CRICKET and CHRONOS Trials
Led the CRICKET trial demonstrating that cetuximab rechallenge in ctDNA-RAS/RAF/EGFR wild-type patients who had previously responded to anti-EGFR therapy produced objective responses in a refractory setting, and the CHRONOS phase II trial using serial ctDNA monitoring to time panitumumab rechallenge, achieving a 30% objective response rate in patients selected by ctDNA absence of resistance mutations — establishing ctDNA-guided rechallenge as a new precision oncology strategy.
Clonal Dynamics of EGFR Resistance — Liquid Biopsy and Rechallenge Biology
Performed landmark studies characterizing the clonal dynamics of acquired resistance to anti-EGFR therapy in mCRC using serial ctDNA sequencing, demonstrating that RAS mutations emerge and then decay after withdrawal of anti-EGFR pressure, that this decay corresponds to restored sensitivity, and that the timeline of clonal evolution follows predictable kinetics — fundamentally advancing the understanding of adaptive resistance in CRC.
EGFR Extracellular Domain Mutations as Mechanisms of Anti-EGFR Resistance
Identified and characterized EGFR ectodomain mutations (S492R and others) as mechanisms of acquired resistance to cetuximab — mutations that impair antibody binding but preserve EGFR signaling — and demonstrated that these mutations are clonal, detectable in ctDNA, and that alternative anti-EGFR antibodies with different epitopes (e.g., panitumumab) can overcome certain ectodomain resistance mutations, informing antibody sequencing strategies.
FOLFOX/FOLFIRI Plus Anti-EGFR in mCRC — European Trial Leadership
Contributed to multiple European cooperative group and industry-sponsored trials investigating anti-EGFR combinations with FOLFOX and FOLFIRI across lines of therapy in RAS wild-type mCRC, providing key data on response rates, toxicity management, and biomarker analyses that informed ESMO guideline recommendations for treatment sequencing.
Representative Works 代表性著作
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-center clinical study (CRICKET)
JAMA Oncology (2019)
CRICKET trial demonstrating the feasibility and activity of ctDNA-RAS/RAF/EGFR wild-type-selected anti-EGFR rechallenge in refractory mCRC, establishing the proof-of-concept for rechallenge as a precision oncology strategy.
ctDNA-guided rechallenge with panitumumab in patients with RAS/BRAF wild-type, anti-EGFR resistant metastatic colorectal cancer: the phase II CHRONOS trial
Nature Medicine (2023)
CHRONOS trial demonstrating 30% ORR with ctDNA-guided panitumumab rechallenge in mCRC patients molecularly re-sensitized after anti-EGFR discontinuation, establishing ctDNA selection as essential for rechallenge strategies.
Acquired resistance to anti-EGFR antibody-based therapy in KRAS-, NRAS-, BRAF- and PI3KCA-wild type colorectal cancer patients
Clinical Cancer Research (2015)
Comprehensive characterization of acquired resistance mechanisms to anti-EGFR therapy in RAS/RAF wild-type mCRC, identifying EGFR ectodomain mutations and RAS/RAF mutations as the dominant resistance drivers detectable via ctDNA.
Cetuximab plus FOLFOX4 or FOLFIRI as first-line treatment for patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
Annals of Oncology (2012)
CECOG randomized phase II study demonstrating high objective response rates with cetuximab plus either FOLFOX4 or FOLFIRI in KRAS wild-type first-line mCRC, informing backbone selection with anti-EGFR therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 福尔图纳托·恰尔迪耶洛 的研究动态
Follow Fortunato Ciardiello's research updates
留下邮箱，当我们发布与 Fortunato Ciardiello（University of Campania Luigi Vanvitelli, Naples）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment